WEBINAR

Synthetic DNA Technologies Enable Fast and Responsive Antibody-based Therapeutics and Diagnostics for SARS-CoV-2

DDN_NEW Logo
RUNNING ON-DEMAND NOW

At ASMS 2019, SCIEX made a technology announcement of Acoustic Ejection Mass Spectrometry (AEMS) which will shortly be commercialized as Echo® MS in early 2020.

This webinar will provide insights into the fundamentals of the technology and how it harnesses the two unique technologies, Acoustic Droplet Ejection (ADE) and the Open Port Interface (OPI), combined with the quantitative power of SCIEX mass spectrometry. Read More Below

Register for the Webinar

Already registered?
Access the webinar here »

Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry.  This solution includes (1) a panel of highly diverse synthetic naïve antibody phage display libraries, (2) several target class specific antibody phage display libraries against difficult-to-drug targets, (3) a Twist Antibody Optimization (TAO) platform for antibody affinity and developability optimization and (4) a high-throughput antibody expression service.  To highlight the power of this platform, our anti-SARS-CoV-2 antibody discovery and optimization efforts will be presented.

Speaker Information:

Webinar Aaron Headshot- July9

Aaron K. Sato, Ph.D.

Chief Scientific Officer, Biopharma

Twist Bioscience

Synthetic DNA Technologies Enable Fast and Responsive SARS-CoV-2 Antibody Discovery and Optimization

Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry. 

Twist Biopharma, a Division of Twist Bioscience

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.

Sponsored by

        twist-full-logo-transparent-250x130_copy 
 

 

 

Interested in sponsoring a webinar?
Click here to contact our friendly sales team.